Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;7(4):100524.
doi: 10.1016/j.esmoop.2022.100524. Epub 2022 Aug 12.

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment

J Thouvenin  1 , C Van Marcke  2 , L Decoster  3 , G Raicevic  4 , K Punie  5 , M Vandenbulcke  4 , R Salgado  6 , E Van Valckenborgh  4 , B Maes  7 , S Joris  3 , D Vander Steichel  8 , K Vranken  9 , S Jacobs  10 , F Dedeurwaerdere  11 , G Martens  12 , H Devos  13 , F P Duhoux  2 , M Rasschaert  14 , P Pauwels  15 , K Geboes  16 , J Collignon  17 , S Tejpar  10 , J-L Canon  18 , M Peeters  19 , A Rutten  20 , T Van de Mooter  20 , J Vermeij  21 , D Schrijvers  22 , W Demey  23 , W Lybaert  20 , J Van Huysse  24 , J Mebis  7 , A Awada  25 , K B M Claes  26 , A Hebrant  4 , J Van der Meulen  26 , B Delafontaine  27 , I Vanden Bempt  28 , J Maetens  4 , M de Hemptinne  4 , S Rottey  29 , P Aftimos  25 , J De Grève  30
Affiliations

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment

J Thouvenin et al. ESMO Open. 2022 Aug.

Abstract

PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the ultimate goal to offer patients with metastatic solid tumors molecularly guided treatments. The PRECISION 1 study has led to the creation of a clinico-genomic database. The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) and GeNeo studies will increase the number of patients with advanced cancer that have comprehensive genotyping of their cancer. The PRECISION 2 project consists of investigator-initiated phase II studies aiming to provide access to a targeted drug for patients whose tumors harbor actionable mutations in case the matched drug is not available through reimbursement or clinical trials in Belgium.

Keywords: genomic alterations; genomic-driven therapy; metastatic tumors; molecular tumor board; next-generation sequencing (NGS).

PubMed Disclaimer

Figures

Figure 1
Figure 1
The PRECISION initiative design. NGS, next-generation sequencing.
Figure 2
Figure 2
Serial computed tomography (CT) scan images illustrating the partial response on afatinib in a patient with metastatic EGFR-mutated pancreatic cancer. EGFR, epidermal growth factor receptor.
Figure 3
Figure 3
Evolution of CA 19-9 on afatinib for a patient with metastatic EGFR-mutated pancreatic cancer. EGFR, epidermal growth factor receptor.
See this image and copyright information in PMC

References

    1. Zehir A., Benayed R., Shah R.H., et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–713. - PMC - PubMed
    1. Hyman D.M., Taylor B.S., Baselga J. Implementing genome-driven oncology. Cell. 2017;168:584–599. - PMC - PubMed
    1. Bedard P.L., Hyman D.M., Davids M.S., Siu L.L. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020;395:1078–1088. - PubMed
    1. Massard C., Michiels S., Ferté C., et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7:586–595. - PubMed
    1. Mackley M.P., Fernandez N.R., Fletcher B., Woolcott C.G., Fernandez C.V. Revisiting risk and benefit in early oncology trials in the era of precision medicine: a systematic review and meta-analysis of phase I trials of targeted single-agent anticancer therapies. JCO Precis Oncol. 2021;5:17–26. - PubMed

Publication types